Are there any scenarios in which you would consider use of PARPi in the upfront mCSPC setting rather than reserving for CRPC?

Community PollStarted

Would you consider the use of PARPi in upfront treatment of mCSPC with BRCA+/HRRm?

40 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers

Mednet MemberInvited Expert

Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty

Answered on

The FDA approved talazoparib plus enzalutamide for HRRm metastatic CRPC in June 2023. NCCN panel recommends talazoparib plus enzalutamide as a category 1 treatment option for patients with metastatic CRPC and a pathogenic mutation (germline and/or somatic) in one of certain HRR and other DNA repair ...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Medical Oncology · The University of Texas Health Science Center at San Antonio

Answered on

Not at this time until more data is released from the ongoing studies such as AMPLITUDE/TALAPRO-3 are published. There are risks of serious bone marrow toxicity such as bone marrow failure, leukemia, and myelodysplastic syndrome with PARPi. (1) Presumably this risk is dose-related and duration-relat...

Join for free or sign in to see the full answer

Mednet Member

Urology · Atlantic Urology Clinics

Answered on

Currently, the only scenario which I would consider is a well designed clinical trial.

Join for free or sign in to see the full answer